Menu Search
Equities

Nipro Corp

8086:TYO

Nipro Corp

Actions
Health CareMedical Equipment and Services
  • Price (JPY)1,375.50
  • Today's Change2.00 / 0.15%
  • Shares traded242.50k
  • 1 Year change+24.54%
  • Beta0.2885
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform2
Hold1
Sell1
Strong Sell0

Share price forecast in JPY

The 4 analysts offering 12 month price targets for Nipro Corp have a median target of 1,470.00, with a high estimate of 1,550.00 and a low estimate of 1,400.00. The median estimate represents a 6.87% increase from the last price of 1,375.50.
High12.7%1,550.00
Med6.9%1,470.00
Low1.8%1,400.00

Dividends in JPY

In 2024, Nipro Corp reported a dividend of 25.00 JPY, which represents a 13.64% increase over last year. The 3 analysts covering the company expect dividends of 33.67 JPY for the upcoming fiscal year, an increase of 34.67%.
Div growth (TTM)13.64%
More ▼

Earnings history & estimates in JPY

On Nov 08, 2024, Nipro Corp reported 2nd quarter 2025 losses of -15.32 per share.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate-53.73%
Nipro Corp reported annual 2024 earnings of 68.12 per share on May 10, 2024.
Average growth rate+23.86%
More ▼

Revenue history & estimates in JPY

Nipro Corporation had 2nd quarter 2025 revenues of 159.63m. This bettered the 155.10m consensus of the 2 analysts covering the company. This was 13.54% above the prior year's 2nd quarter results.
Average growth rate+2.45%
Nipro Corporation had revenues for the full year 2024 of 586.79m. This was 7.63% above the prior year's results.
Average growth rate+7.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.